Mr. Paese joined Profectus BioSciences in 2009, when he was appointed to the Board of Directors as Chairman. He assumed the role of Executive Chairman in January 2010. He has extensive experience in healthcare and strong ties to Profectus through the Institute of Human Virology, where he has been a member of the Advisory Board since 2003. In addition, Mr. Paese served as Vice President & General Counsel for NovaCare, Inc., a New York Stock Exchange (NYSE) listed company. Prior to NovaCare, he co-founded a successful start-up medical rehabilitation company, Rehab Systems Company, and secured three rounds of venture capital funding totaling $14M. He coordinated a lucrative acquisition by NovaCare, Inc., after positioning the company for a possible initial public offering. Currently, he serves as the practice manager for government relations with Buchanan Ingersoll & Rooney. Prior to this current position, he served the Commonwealth of Pennsylvania as Secretary of Administration to Governor Tom Ridge, where he advised the Governor on key executive branch functions, including healthcare matters. He earned his BA in Government and International Relations from the University of Notre Dame in South Bend, Indiana and his Juris Doctor from Dickinson School of Law in Carlisle, Pennsylvania.
Prior to being appointed as President in 2013, Mr. Meshulam had joined the Company in 2005 as the Chief Operating Officer. Mr. Meshulam was Director of Corporate Development at the Institute of Human Virology from 1996-2004. He has also held various positions in the biotechnology industry including founder, Cellular Products, Inc. where he held various positions from 1983-1996, including Chairman CEO, President CEO and Executive Vice-President. Cellular Products was a small publicly held biotechnology company specializing in the development, manufacturing and marketing of blood screening and research assays for human retroviruses. Under his leadership, Cellular Products developed, conducted clinical trials, received FDA approval, produced and marketed blood screening assays for HIV and HTLV-I. Cellular Products also was first to commercialize a kit for detecting HIV p24. In his positions with Cellular Products, Mr. Meshulam was directly responsible to develop and oversee joint development projects with small and large corporations which ultimately lead to the commercialization of two products that were FDA approved and in excess of 100 products for research use. Mr. Meshulam also served as President of Northern Scientific, Inc. a small ophthalmic manufacturer prior to him selling all manufacturing rights to Chiron. Northern Scientific was the sole commercial provider of MK Corneal Storage Media a vital product for the storage and transport of corneas for transplant internationally. Mr. Meshulam received a BA in Biology from SUNY Buffalo in 1979.
Prior to joining Profectus BioSciences in 2008, Dr. Eldridge was Vice President of Advanced Vaccines Research for Wyeth Vaccines Research and oversaw the departments of Immunobiology, Bacteriology, and Cell Biology and Pathogenesis. He directed the research of approximately 147 scientists in these areas and was actively engaged in Wyeth's Vaccine discovery and development programs. Dr. Eldridge has substantial practical experience in the management of vaccine programs in all phases of development. As a Principal Investigator, his research has been supported by grants and contracts from the NIH and the DoD. He is currently the Principal Investigator on two HIV Vaccine Design and Development Team Contracts from the NIH. The FDA has recently approved the INDs for three clinical trials to be initiated under these contracts. Dr. Eldridge is the inventor on 11 issued patents, and author of over 130 scientific papers that have appeared in peer-reviewed journals, as well as author of over 10 review articles and book chapters. Prior to joining Wyeth (Lederle-Praxis), he held various faculty positions at the University of Alabama, Birmingham from 1984 to 1993. He continues as an Adjunct Associate Professor, Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama. Dr. Eldridge received his Ph.D. in Microbiology in 1981 from State University of New York at Buffalo.
Alan M. Gordon is Corporate Counsel for Profectus where he focuses on intellectual property and technology transfer matters. Prior to joining Profectus in 2010, Mr. Gordon headed the Vaccines Patent Group for 10 years at Wyeth, where he supervised attorneys handling patent matters for a $3 billion business unit. Prior to entering corporate practice, Mr. Gordon was an associate at a New York City patent firm specializing in litigation. Mr. Gordon has a J.D. from the Syracuse University College of Law and a B.S. in Biochemistry from the SUNY College of Environmental Science and Forestry (both degrees with honors).
Dr. Egan joined Profectus Bioscience in 2008. Prior to that, Dr. Egan was with Wyeth Vaccines Research where he evaluated candidate HIV-1 vaccines in mice, guinea pigs, non-human primates and in phase I clinical trials. Dr. Egan received his Ph.D. in Immunology from the Johns Hopkins University School of Medicine and went on to do his postdoctoral training at Harvard Medical School. While at Harvard, Dr. Egan worked to evaluate the immunogenicity of several prototype plasmid DNA vaccines for HIV-1 in the rhesus macaque SHIV challenge model. Dr. Egan has served on numerous NIH scientific review committees and has numerous publications to his credit in the area of vaccine research and development. Dr. Egan brings to Profectus 15+ years of HIV and HIV vaccine research experience and significant experience with state-of-the-art immunological assays for monitoring cellular immune responses in animals and in clinical studies.
Prior to joining Profectus in 2008, Dr. Clarke was a Principle Scientist at Wyeth Vaccines for 12 years where he was the Project Leader responsible for the development of the vaccine vector platforms based on recombinant forms of Vesicular Stomatitis Virus (rVSV) and related viruses. Prior to Wyeth, he was with Aviron where he was the Project Leader responsible for the development of a RSV (Respiratory Syncytial Virus) vaccine. Dr. Clarke earned his Ph.D. from the laboratory of Dr. Bert Rima at the Queen's University of Belfast where he studied canine distemper virus (CDV). He did his post-doctoral work with Dr John Holland at University of California, San Diego where he used VSV to model virus population dynamics. Within Profectus, Dr. Clarke is responsible for the construction and development of all rVSV based vaccines within the compaany's portfolio.
Mr. Tremblay joined Profectus BioSciences in 2008 to establish and maintain Quality Systems to support the manufacture and testing of clinical trial materials (CTMs). Mr. Tremblay has 25 years of experience in the biopharmaceutical, pharmaceutical, and vaccine industries. Prior to joining Profectus, he was Associate Director of Global Compliance Auditing—Research, cGMP for Wyeth, where he was responsible for managing a corporate global GMP Compliance Program for development activities and supported pharmaceuticals, vaccines, consumer healthcare, and biotechnology products. Mr. Tremblay also managed the rehearsal Pre-Approval Inspection (PAI) audit program at Wyeth, performing compliance audits of facilities filing NDAs/BLAs in advance of the on-site FDA PAI inspections to support inspection readiness activities. Prior to his Wyeth tenure, Mr. Tremblay worked in quality assurance roles for Protein Design Labs, SmithKline Beecham, Synergen, and Verax Corporation. He has a B.A. in Biology from New York University.